Our Alliance
Mission of the ILD Community Network
To unite, empower, and support individuals and organizations in advancing awareness, research, and care for those impacted by Interstitial Lung Disease.
Connect to ILD experts in your region
Partner with trusted ILD experts in your region to unlock your potential and achieve your goals.
ILD EXPERTS
Naomi Amudala
CRNP, MSN
Naomi Amudala, CRNP, MSN, is a highly experienced nurse practitioner specializing in rheumatology at Penn Medicine in Philadelphia, Pennsylvania. After graduating from MGH Institute of Health Professions in 2009 with a Master’s in Nursing, Naomi joined the division of Rheumatology at Boston University. Her primary focus was evaluating and managing patients with vasculitis as well as acting as co-investigator in multiple clinical trials in vasculitis. In 2018 she moved to Philadelphia and started working at Penn Medicine Rheumatology. The majority of her time continues to be dedicated to the clinical care of patients with vasculitis and other rare diseases as well as engaging in research. In 2022 Naomi joined the board of directors for RhAPP, which is a national organization for APPs and pharmacists in Rheumatology.
Christine Anderson
NP-C
Christine Anderson, NP-C, is a nurse practitioner specializing in pulmonology at Duke Health in Durham, North Carolina. She is originally from Canada and graduated from The University of Western Ontario with a Bachelors in Science in Nursing in London, Ontario back in 1999. After graduation, she moved to Durham, NC to start a nursing career at Duke University Health System. The majority of her nursing career has been in cardiology from Cardiac Step-Down to Cardiac Intensive Care Unit to the Cardiac Cath Lab. In 2005, Christine obtained a Masters in Science in Nursing with a Leadership focus and became the nurse manager of the Electrophysiology Lab at Duke Hospital. After downsizing the department, she moved over to the Duke Clinical Research Institute as a nurse clinician working on cardiology clinical trials. She truly missed patient care and went back to school and graduated with a post-master’s certificate as an Adult-Gerontologic Nurse Practitioner in 2015. Christine worked at Duke Cardiology of Lumberton for one year before coming back to main campus of Duke University Hospital and starting a new career in pulmonary medicine. Now she is the nurse practitioner for the Duke Interstitial Lung Disease Clinic where she still practices. For her last hurrah, Christine went back to school for a Doctorate of Nursing Practice degree that was awarded in 2019. Her graduate project was “Using a Smart Phrase to Improve Documentation of Supportive Care Measures in Patients with IPF”. This paper was published in the Journal for Nurse Practitioners and was presented at conferences such as the Pulmonary Fibrosis Foundation and Chest. Christine loves working with ILD patients and have learned so much over the past 9 years working in our clinic. She have been speaking about IPF and progressive ILD for past several years and have so much fun sharing my knowledge with Advanced Care Providers and providers alike.
Lisa Asfahani
PA-C
Lisa Asfahani DHSc, PA-C is a certified and state licensed Physician Assistant practicing in Rheumatology at Southland Arthritis in Temecula, California. Lisa graduated from California State Polytechnic University with a Bachelor’s degree in Biology, her Master’s degree in Physician Assistant Sciences from Loma Linda University in 2011 and her Doctorate degree in Health Sciences from A.T. Still University of Health Sciences in 2022. Lisa is experienced in both Rheumatology as well as in General Medicine and involved in numerous clinical studies in the field of Rheumatology. She is a member of several professional societies including the Association of Rheumatology Professionals (ARP), California Academy of Physician Assistants (CAPA), and RhAPP. Lisa’s goal in patient care is to treat each patient/provider interaction as an opportunity serve, to teach, and to heal. She enjoys traveling and spending time with family whenever she can.
Heather Bachert
NP
Heather D. Bachert, NP, is a board-certified Adult Nurse Practitioner and specializes in interstitial lung disease (ILD) and pulmonary fibrosis (PF) at Henry Ford Hospital in Detroit, Michigan. She earned her advanced practice training at Wayne State University and the University of Saskatchewan and is certified by the American Nurses Credentialing Center. In addition to her clinical role, Heather leads patient support groups for individuals living with ILD and PF, providing education, guidance, and a sense of community. Known for her compassionate and thorough approach, she is highly regarded by patients for her ability to explain complex conditions clearly and provide attentive follow-up care. She is currently accepting new patients and also offers telehealth services.
Shannon Benesh
DNP, NP-C
Shannon Benesh, DNP, RN-BC, AGNP-C, is a Nurse Practitioner specializing in Interstitial Lung Disease at Columbia University Irving Medical Center within the Division of Pulmonary and Critical Care. She earned her BSN from James Madison University and her MSN from Adelphi University, later completing her Doctor of Nursing Practice at Stony Brook University with a project focused on early advance care planning in ILD. Shannon has clinical experience as an RN at leading academic hospitals across various specialties and is certified as a Progressive Care Certified Nurse and Adult-Gerontology Nurse Practitioner. She is an active member of AANP, has contributed to published ILD research, and participates in national advisory boards dedicated to improving ILD care. She lives in Brooklyn with her husband and their dog and enjoys traveling, reading, running, and the occasional cocktail.
Kelley Brant
NP
Kelley Brant, NP, is a nurse practitioner specializing in pulmonology at Intermountain Health in Salt Lake City, Utah. With over 17 years of diverse clinical experience, Kelley Brant is a dedicated healthcare professional with a passion for advancing pulmonary care. A graduate of San Diego State University with a BSN, Kelley began her career as a registered nurse in high-acuity settings, including the emergency room, ICU, and urgent care, where she honed her ability to excel in fast-paced, multidisciplinary environments. Kelley earned her MSN from the University of South Alabama and is double board-certified as a Family Nurse Practitioner and Emergency Nurse Practitioner. For the past 2.5 years, Kelley has served as a nurse practitioner specializing in pulmonary medicine, with a particular focus in interstitial lung disease (ILD). As an ILD program coordinator, Kelley has gained experience in managing complex patient populations and remains actively involved in general pulmonary care, including COPD, asthma, and other respiratory conditions. Kelley also has a strong interest in research, supporting her facility’s participation in several randomized controlled trials to advance evidence-based practice. Beyond clinical work, Kelley is committed to fostering connections within the healthcare community. As a member of AANP, CHEST, and Utah Nurse Practitioners, she emphasizes professional development and collaboration to improve patient outcomes and advance the field of pulmonary care.
Michele Cerra
MSN, FNP-BC
April Conlon
NP-C
Kelsey Cramer
MSN, AGACNP-BC, DNP
Kelsey Cramer, MSN, AGACNP-BC, DNP, is a board-certified adult-gerontology acute care nurse practitioner specializing in pulmonary medicine at Froedtert & the Medical College of Wisconsin. She focuses on interstitial lung disease (ILD), pulmonary hypertension (PH), and sarcoidosis. Kelsey earned her MSN from Depaul University in Chicago, and her DNP from Rush University. She is dedicated to delivering patient-centered care, education, and support for those managing complex lung conditions.
Kristy Delaney
APRN
Kristy Delaney, APRN, is a pulmonary nurse practitioner specializing in interstitial lung disease at The University of Kansas Health System. She has over 21 years of experience in medicine, beginning her career as a bedside RN in the Medical ICU before becoming an APRN. For the past 9 years, she has focused her practice on ILD. In addition to her clinical expertise, Kristy holds a degree in Education and is passionate about empowering patients, caregivers, and fellow healthcare professionals through education and support in the management of ILD.
Rebekah Edwards
DNP, FNP-C
Rebekah Edwards, DNP, FNP-C, is a nurse practitioner specializing in pulmonology at Norton Thoracic Institute, St. Joseph’s Hospital and Medical Center in Phoenix, Arizona. She received her Bachelor of Science in Nursing from Arizona State University and is experienced in pulmonology, cardiology, and thoracic surgery. She also received her Doctorate of Nursing Practice from Arizona State University and has practiced in pulmonology ever since.
Mary Elliott
PA-C, PhD
Kathryn Fenwick
CRNP, DNP
Heather Finlayson
PA-C
Heather Finlayson, MS, PA-C, is a certified Physician Assistant specializing in rheumatology for Summit Rheumatology in Littleton, Colorado. She previously worked at National Jewish Health Rheumatology and started at Colorado Arthritis Associates in Rheumatology in 2012. She has also taught rheumatology courses at Rocky Vista University PA program since 2022. Heather is a member of the Association of Rheumatology Professionals (ARP) (division of American College of Rheumatology-ACR), and the Association of Women in Rheumatology (AWIR). She is currently the AWIR Denver Local Chapter Co-Lead, a Rheumatology Advanced Practice Providers (RhAPP) faculty member and has served on several ACR/ARP committees.
Cori Fratelli
MSN, FNP-C
Cori Fratelli, MSN, FNP-C, is a nurse practitioner specializing in pulmonology at National Jewish Health in Denver, Colorado. She has a unique background in both basic science and clinical research, which has informed her interest in clinical medicine. Her past basic science research includes asthma, airway hyperresponsiveness, cystic fibrosis, and lung cancer. Her past clinical research includes COPD and interstitial lung disease (ILD). Presently, she is interested in how research translates into personalized medicine. Her clinical focus is mainly on ILD, but she also sees general pulmonary medicine patients, as needed.
Kyle George
PA-C
Kyle George, PA-C, is a physician assistant with over 16 years of experience in rheumatology at Saint Luke's Medical Center in Boise, Idaho. He specializes in managing autoimmune diseases such as rheumatoid arthritis and osteoporosis. Kyle collaborates with a multidisciplinary team, providing personalized and comprehensive care to his patients.
Shannon Ghizzoni
PA-C
Shannon Ghizzoni, PA-C, is a board-certified Physician Assistant specializing in rheumatology at the Columbus Arthritis Center in Columbus, Ohio. With a passion for providing comprehensive care to patients with rheumatic conditions, Shannon focuses on patient education, disease management, and improving quality of life. She is dedicated to staying current with the latest advancements in rheumatology and fostering collaborative relationships with patients and healthcare teams to deliver personalized, evidence-based care.
Courtney Gibbons
NP
Courtney Gibbons, MSN, APRN, AGACNP-BC, is a dedicated Pulmonary Nurse Practitioner. With empathy, and compassion, Courtney is committed to delivering evidence-based, patient-centered care to individuals living with complex lung conditions. Her nurse practitioner career has been devoted to pulmonary medicine, to improve quality of life and empower patients. Courtney earned her License at Tyler Junior College then advanced to Registered Nurse in 2016 after completing her Bachelor of Science in Nursing at Indiana State University, and later earned her Master of Science in Nursing with an Adult-Gerontology Acute Care Nurse Practitioner Certification from the University of Texas at Arlington in 2021. Throughout her career, Courtney has been recognized for her dedication to clinical excellence and compassionate care, receiving the Houston Methodist ICARE Award and being named among the Houston Chronicle’s Top 150 Nurses of 2020.
Audrey Gibson
PA-C, MsPAS
Audrey Gibson, MSPAS, PA-C is a board-certified rheumatology physician assistant at the Arthritis Center of North Georgia in Gainesville, Georgia. She holds dual bachelor’s degrees in biology and psychology from Lipscomb University and earned her Master of Science in Physician Assistant Studies from South University in Savannah, Georgia. Audrey is a certified densitometrist with a clinical focus on rheumatoid arthritis, psoriatic arthritis, lupus, spondyloarthropathies, inflammatory myopathies, and osteoporosis. She is an active member of the Society of Physician Assistants in Rheumatology, the Georgia Society of Rheumatology, the American College of Rheumatology, and the American Academy of Physician Assistants. Audrey also serves as a faculty advisor for the Rheumatology Advanced Practice Providers (RhAPP).
Jessica Glennie
CNP
Jessica Glennie, CNP, is a certified nurse practitioner, specializing in pulmonology, who has worked in outpatient pulmonary medicine at the Cleveland Clinic in Cleveland, Ohio for 8 years. She manages patients in the interstitial lung disease program, including care of patients with idiopathic pulmonary fibrosis, autoimmune related interstitial lung disease, hypersensitivity pneumonitis, occupational lung diseases, and drug-induced interstitial lung disease. She is co-director of the Cleveland Clinic’s ILD multidisciplinary conference.
ILD Community Network Educational Events
ILD Digital Learning Center
Podcasts
Podcasts
Advances in IPF Clinical Trials
August 2026
29:40 m
In this ILD Community Network Podcast episode, host Kelsey Cramer is joined by Kristy Delaney for a timely discussion on advances in idiopathic pulmonary fibrosis clinical trials and the evolving treatment landscape for IPF and progressive pulmonary fibrosis. Together, they review the TETON clinical development program, including TETON 1, TETON 2, and TETON PPF, and explore the scientific rationale for studying inhaled treprostinil in pulmonary fibrosis following findings from the INCREASE trial. This episode highlights key clinical trial insights related to forced vital capacity, disease progression, time to clinical worsening, background anti-fibrotic therapy, safety, tolerability, cough management, and the potential role of inhaled therapy as an add-on or alternative option for patients with IPF or PPF. Clinicians will gain practical perspective on emerging IPF research, patient selection for new therapies, treatment layering strategies, clinical trial considerations, and how advanced practice providers can stay informed as therapeutic options for interstitial lung disease continue to expand.
The Role of APPs in Advanced ILD/PH ILD
August 2026
18:12 m
In this ILD Community Network podcast episode, host Kelsey Cramer is joined by Jenny Williams, for a practical discussion on the role of advanced practice providers in advanced interstitial lung disease and pulmonary hypertension associated with interstitial lung disease, also known as PH-ILD. Together, they explore how APPs can recognize high-risk signs of disease progression, including worsening shortness of breath, declining exercise tolerance, increasing oxygen needs, changes in pulmonary function tests, reduced six-minute walk distance, and signs of right heart strain or pulmonary hypertension. This episode also highlights when clinicians should consider referral to ILD specialty centers, pulmonary hypertension clinics, lung transplant evaluation, pulmonary rehab, anti-fibrotic therapy, inhaled therapy for PH-ILD, and palliative care support. Listeners will gain practical insights into identifying advanced ILD, understanding PH-ILD risk factors, recognizing transplant referral triggers, coordinating multidisciplinary care, and ensuring patients receive timely access to specialized treatment and advanced therapies.
How To Differentiate ILD Progression vs Treatment Failure
July 2026
25:23 m
In this episode of the ILD Community Network Podcast, host Amanda Mixon, PA-C, is joined by Jenny Williams, PA-C, for a practical discussion on how clinicians can differentiate interstitial lung disease progression from treatment failure. Together, they explore the clinical, physiologic, and radiographic clues that may signal progressive pulmonary fibrosis, including worsening shortness of breath, cough, declining FVC or DLCO, increased oxygen needs, and high-resolution CT findings such as worsening fibrosis, traction bronchiectasis, honeycombing, and volume loss. This episode also highlights the importance of ruling out other causes of respiratory symptoms, including pulmonary hypertension, cardiac disease, pulmonary embolism, anemia, deconditioning, reflux, aspiration, and infection, before determining whether a patient’s current ILD therapy is no longer working. Listeners will gain practical insights into pulmonary function test monitoring, imaging follow-up, treatment escalation, anti-fibrotic therapy, multidisciplinary collaboration, and referral to ILD specialty centers to help improve long-term outcomes for patients living with interstitial lung disease.
Podcast: Recognizing PH-ILD Earlier: Missed Signals, Delayed Diagnosis, and How to Close the Gap
February 2026
31:14 m
Pulmonary hypertension associated with interstitial lung disease (PH-ILD) is one of the most impactful—and often underrecognized—complications in patients with established ILD, frequently presenting with symptoms that mimic ILD progression. In this ILD Community Network podcast episode, Amanda Mixon is joined by Corinne Young to break down why PH-ILD is missed, what red flags clinicians should watch for, and when to escalate evaluation beyond “worsening ILD.” The discussion highlights practical screening cues such as disproportionate DLCO decline, stable imaging with worsening dyspnea, enlarged pulmonary arteries on high-resolution CT, and revealing echocardiogram findings including RV/RA enlargement, TAPSE, and tricuspid regurgitation—along with the limitations of echo estimates and the role of right heart catheterization for confirmation. Tune in for real-world strategies to improve earlier recognition, reduce diagnostic delays, and strengthen multidisciplinary collaboration between rheumatology, pulmonology, and primary care to improve outcomes for patients living with ILD and PH-ILD. #InterstitialLungDisease #PulmonaryHypertension #PHILD #Rheumatology #Pulmonology #AdvancedPracticeProviders #MedicalEducation #ILDCommunityNetwork #APAPP #RhAPP
ILD & PH-ILD at the Rheum–Pulm Crossroads
November 2025
22:52 m
Join host Amanda Mixon, President of RhAPP, for a special episode recorded live at the 6th Annual RhAPP Conference. In this conversation, Amanda is joined by Jessica Glennie, CNP, from the Cleveland Clinic, to explore the complex intersection of rheumatology and pulmonology, focusing on Interstitial Lung Disease (ILD) and Pulmonary Hypertension in ILD (PH-ILD). Together, they unpack how early recognition, multidisciplinary collaboration, and evidence-based management can improve outcomes for patients with connective tissue disease–related pulmonary complications. Tune in for expert insights, practical diagnostic tips, and highlights from one of the most engaging sessions of the RhAPP National Conference.
Evolving IPF Care: The Significance of Nerandomilast’s FDA Approval
October 2025
25:20 m
In this special crossover episode, host Amanda Mixon, PA-C, President of RhAPP, sits down with Corinne Young, FNP-C, founder and President of the Association of Pulmonary Advanced Practice Providers (APAPP), to discuss one of the most exciting developments in interstitial lung disease: the FDA approval of nerandomilast for idiopathic pulmonary fibrosis (IPF). This breakthrough marks the first new IPF therapy in more than a decade and introduces a novel PDE4B mechanism of action designed to reduce fibrosis and improve lung function. Together, Amanda and Corrine unpack the clinical data behind nerandomilast, key findings from the FIBRONEER-IPF trial, and how its safety profile—particularly reduced GI side effects—may reshape treatment pathways and patient quality of life. The conversation also highlights the overlap between rheumatology and pulmonology in managing fibrotic lung diseases and the importance of interdisciplinary collaboration as additional indications for progressive pulmonary fibrosis (PPF) are anticipated. #Rheumatology #Pulmonology #InterstitialLungDisease #IPF #Nerandomilast #Fibrosis #AdvancedPracticeProviders #APPs #FDAApproval #ClinicalUpdates
Rheumatology in the Lungs
July 2025
24:47 m
How can Advanced Practice Providers (APPs) in rheumatology and pulmonology collaborate more effectively to manage interstitial lung disease (ILD) and connective tissue diseases (CTDs)? In this engaging episode of the APAPP Broadcast, recorded live at the Second Annual National APAPP Conference in Nashville, experts Jessica Glennie, PA-C (Cleveland Clinic), Amanda Mixon, PA-C (Colorado), and Cori Fratelli, NP (National Jewish Health) explore clinical overlaps between autoimmune rheumatic diseases and lung involvement, such as ILD in rheumatoid arthritis, systemic sclerosis (scleroderma), Sjögren’s syndrome, and myositis. The panel shares clinical pearls on: -How to recognize signs of CTDs in pulmonary patients -The importance of labs and imaging in early diagnosis -What rheumatology APPs should ask about pulmonary symptoms -The power of cross-specialty collaboration -Real-world case insights, including navigating bird-related hypersensitivity pneumonitis
Immunology of the Lung Podcast
July 2025
11:40 m
Tune in from the Annual APAPP National Conference for a dynamic episode of the APAPP Podcast featuring Corinne Young, FNP-C, Amanda Michaud, PA-C, and Brian Bizik, PA-C—three expert APPs leading engaging sessions on lung immunology, rare immune deficiencies, and COPD updates. Amanda breaks down the “Immunology of the Lung 101” and her “Finding the Zebras” series, where she highlights key red flags for primary immune deficiencies, sharing real patient cases and diagnostic tips to help clinicians recognize and manage these commonly missed conditions. Brian shares practical takeaways from the latest GOLD COPD guidelines, including how biomarkers like eosinophil counts can guide personalized inhaled corticosteroid decisions. Whether you're managing patients with asthma, COPD, or unexplained recurrent infections, this episode delivers clinical pearls you can apply in your practice right away. Discover why this APP-led meeting stands out as a must-attend event for pulmonary and immunology providers. Be sure to like, subscribe, and follow us for more expert-driven conversations.
ILD 101, ILD 102, ILD Peds
July 2025
20:57 m
Join Jessica Glennie, APRN, Naomi Miyazawa, PA-C, and Cori Fratelli, FNP, from the 2025 APAPP National Conference as they explore pediatric and adult interstitial lung disease (ILD). This episode covers diagnosis, disease progression, anti-inflammatory and anti-fibrotic therapies, and the importance of multidisciplinary care. Learn about pediatric ILD (CHILD), autoimmune-related ILD, and new treatment guidelines—all through real-world clinical insights.
Advancing ILD & PH-ILD Care
July 2025
21:35 m
Join Jessica Glennie, APRN, and Lori Reed, FNP, from the 2025 APAPP National Conference as they discuss key insights in diagnosing and managing interstitial lung disease (ILD) and pulmonary hypertension (PH). From interpreting PFTs and recognizing red flags to exploring current and emerging therapies like inhaled treprostinil and neuredomast, this episode offers practical strategies for improving patient care. Tune in for expert tips and updates every pulmonary provider should know.
Practical Considerations for Screening for PH in ILD Clinics
July 2025
17:17 m
In this insightful Podcast, expert advanced practice providers, Corinne Young & Jessica Glennie share practical strategies for identifying and screening for pulmonary hypertension (PH) in patients with interstitial lung disease (ILD). They discuss how to recognize subtle red flags—such as declining DLCO, changes in walk test performance, and discrepancies in pulmonary function test results—that may indicate the presence of PH. The conversation also covers when to order echocardiograms, when to refer for right heart catheterization, and how to distinguish ILD progression from the development of PH. With a focus on multidisciplinary collaboration and real-world clinical workflows, this episode offers valuable, actionable guidance for APPs, pulmonologists, and care teams managing ILD populations.
Understanding MAC with Jennifer Faber- Gerling
December 2024
30:30 m
In this episode, Corinne Young interviews Jennifer Faber- Gerling about mycobacterium avian complex (MAC). They discuss the bacterium itself, the rise in cases, screening and diagnosis, treatment and side effects, reinfection versus reactivation, and symptom management. Jennifer emphasized the importance of close surveillance, collaboration with a multidisciplinary team, and individualized care for patients with MAC.
Idiopathic Shortness of Breath Part 1 Using CPET
December 2024
26:37 m
National Jewish Health’s NP, Cori Fratelli, shares with us how she and her colleagues utilize CPET and other testing in patients with unexplained shortness of breath.
Idiopathic Shortness of Breath part 2 Dysfunctional Breathing Clinic
December 2024
29:41 m
Nurse practitioner Cori Fratelli from National Jewish Health discusses breathing pattern disorders, related to unexplained dyspnea. Cori advocates to consider these disorders, discusses treatment methods like breath retraining, inspiratory muscle training, and emphasizes the need for more research and specialized clinics.
Deep Dive Into ILD Therapeutics
December 2024
37:59 m
Check out this podcast recording from the 2024 APAPP Conference in Vegas!
FAQ
FAQ
FAQ: How Can Pulmonology and Rheumatology Providers Coordinate Earlier PH-ILD Diagnosis?
August 2026
01:33 m
In this ILD Community Network video, Kelsey Cramer, NP, an interstitial lung disease and pulmonary hypertension specialist from the Medical College of Wisconsin and Froedtert Hospital, discusses how pulmonology and rheumatology providers can better coordinate earlier diagnosis of pulmonary hypertension in patients with interstitial lung disease. She highlights the importance of building multidisciplinary connections, creating trusted referral pathways, and reaching out to colleagues across specialties to improve patient care. This episode also reviews key diagnostic tools that can support earlier PH recognition, including echocardiograms, high-resolution CT scans, pulmonary function tests, diffusion capacity, forced vital capacity, and right heart catheterization. Clinicians will gain practical insight into identifying red flags, such as a DLCO that is out of proportion to FVC, and learn how earlier testing and collaboration can help guide therapy, speed diagnosis, and improve outcomes for patients living with ILD and pulmonary hypertension.
How can clinicians distinguish PH-ILD from progression of interstitial lung disease alone?
February 2026
08:11 m
In this clinical update, Jessica Glennie, CNP, from the Cleveland Clinic Interstitial Lung Disease Group, explains how to differentiate worsening interstitial lung disease (ILD) or progressive pulmonary fibrosis (PPF) from developing or worsening pulmonary hypertension (PH). Because patients often present with overlapping symptoms such as shortness of breath, fatigue, and decreased exercise tolerance, she outlines a practical diagnostic approach using NT-proBNP, spirometry (FVC), DLCO trends, the FVC/DLCO ratio, six-minute walk testing, high-resolution CT imaging, echocardiogram findings (including RVSP and TAPSE), and when to consider right heart catheterization. This concise review helps clinicians determine whether pulmonary hypertension or ILD progression is driving a patient’s decline and supports more informed clinical decision-making.
What Were The Key Findings From the FIBRONEER-IPF Study?
October 2025
03:51 m
In this FAQ video, Corinne Young, FNP-C, founder and president of the Association of Pulmonary Advanced Practice Providers (APAPP), breaks down the pivotal FIBRONEER-IPF Phase 3 trial evaluating nerandomilast, a novel oral PDE4B inhibitor for patients with idiopathic pulmonary fibrosis (IPF). This randomized, double-blind, placebo-controlled study assessed nerandomilast both as monotherapy and in combination with existing antifibrotic therapies such as pirfenidone and nintedanib. Over 52 weeks, investigators observed that nerandomilast slowed lung function decline (FVC), reduced exacerbations and hospitalizations, and demonstrated a safety profile comparable to placebo, with notably fewer gastrointestinal side effects than traditional antifibrotics. These findings mark an exciting advancement in IPF management, offering clinicians a new therapeutic option that may improve both tolerance and long-term outcomes. #IPF #Nerandomilast #FIBRONEERIPF #Pulmonology #AntifibroticTherapy #PDE4B #InterstitialLungDisease #AdvancedPracticeProviders #APPs #ClinicalTrials #FDAApproval
Med Review
Med Review
Recommended Dosing Strategy For Nerandomilast and Key Adverse Effects To Watch For
December 2025
03:42 m
In this medication review, Corinne Young, Pulmonary Nurse Practitioner and President of the Association of Pulmonary Advanced Practice Providers (APAPP), provides a clear overview of nerandomilast, a newly approved therapy for idiopathic pulmonary fibrosis (IPF). Corinne explains recommended dosing strategies—including 18 mg twice daily as the target dose—along with when to use alternative dosing in combination with pirfenidone or nintedanib, and important considerations for patients taking CYP3A inhibitors. She also reviews the key adverse effects clinicians should monitor, including diarrhea, GI symptoms, mood changes, fatigue, dizziness, headache, and potential allergic reactions. This concise breakdown helps clinicians understand how to dose nerandomilast safely, manage side effects, and optimize treatment for patients with IPF. #IPF #IdiopathicPulmonaryFibrosis #PulmonaryCare #Nerandomilast #IPFTreatment #PulmonaryFibrosis #InterstitialLungDisease #ILD #APPeducation #PulmonaryAPP
Webcast
Webcast
Recognizing and Managing RA-Associated ILD
September 2026
20:17 m
This webcast features a case-based discussion on recognizing and managing rheumatic disease-associated interstitial lung disease (ILD), including rheumatoid arthritis-associated ILD and systemic sclerosis-associated ILD. Through practical clinical scenarios, Alanna Kavanaugh, EdD(c), FNP-BC, MSN, BSN, CCRN reviews key warning signs such as progressive shortness of breath, dry cough, inspiratory crackles, exertional oxygen desaturation, reduced DLCO, and high-risk serologic findings. The session highlights early screening with pulmonary function tests and high-resolution CT, identification of UIP and honeycombing patterns, and treatment considerations involving immunomodulatory and antifibrotic therapies. Multidisciplinary collaboration, patient education, close monitoring, infection prevention, and timely lung transplant evaluation are also emphasized to help slow ILD progression and preserve lung function.
Recognizing and Managing RA-Associated ILD
August 2026
34:05 m
This webcast features a case-based discussion on recognizing and managing rheumatic disease-associated interstitial lung disease (ILD), including rheumatoid arthritis-associated ILD and systemic sclerosis-associated ILD. Through practical clinical scenarios, Audrey Gibson, MSPAS, PA-C and Lori Reed, NP review key warning signs such as progressive shortness of breath, dry cough, inspiratory crackles, exertional oxygen desaturation, reduced DLCO, and high-risk serologic findings. The session highlights early screening with pulmonary function tests and high-resolution CT, identification of UIP and honeycombing patterns, and treatment considerations involving immunomodulatory and antifibrotic therapies. Multidisciplinary collaboration, patient education, close monitoring, infection prevention, and timely lung transplant evaluation are also emphasized to help slow ILD progression and preserve lung function.
Recognizing and Managing RA-Associated ILD
August 2026
15:21 m
This webcast features a case-based discussion on recognizing and managing rheumatic disease-associated interstitial lung disease (ILD), including rheumatoid arthritis-associated ILD and systemic sclerosis-associated ILD. Through practical clinical scenarios, Janine Shinn, PA-C and Jasmine EcElhany, MPAS, PA-C review key warning signs such as progressive shortness of breath, dry cough, inspiratory crackles, exertional oxygen desaturation, reduced DLCO, and high-risk serologic findings. The session highlights early screening with pulmonary function tests and high-resolution CT, identification of UIP and honeycombing patterns, and treatment considerations involving immunomodulatory and antifibrotic therapies. Multidisciplinary collaboration, patient education, close monitoring, infection prevention, and timely lung transplant evaluation are also emphasized to help slow ILD progression and preserve lung function.
Recognizing and Managing RA-Associated ILD
August 2026
17:04 m
This webcast features a case-based discussion on recognizing and managing rheumatic disease-associated interstitial lung disease (ILD), including rheumatoid arthritis-associated ILD and systemic sclerosis-associated ILD. Through practical clinical scenarios, Lanier O'Hare, CRNP review key warning signs such as progressive shortness of breath, dry cough, inspiratory crackles, exertional oxygen desaturation, reduced DLCO, and high-risk serologic findings. The session highlights early screening with pulmonary function tests and high-resolution CT, identification of UIP and honeycombing patterns, and treatment considerations involving immunomodulatory and antifibrotic therapies. Multidisciplinary collaboration, patient education, close monitoring, infection prevention, and timely lung transplant evaluation are also emphasized to help slow ILD progression and preserve lung function.
Recognizing and Managing RA-Associated ILD
August 2026
42:05 m
This webcast features a case-based discussion on recognizing and managing rheumatic disease-associated interstitial lung disease (ILD), including rheumatoid arthritis-associated ILD and systemic sclerosis-associated ILD. Through practical clinical scenarios, Alanna Kavanaugh, EdD(c), FNP-BC, MSN, BSN, CCRN and Mary Elliott, PA-C, PhD review key warning signs such as progressive shortness of breath, dry cough, inspiratory crackles, exertional oxygen desaturation, reduced DLCO, and high-risk serologic findings. The session highlights early screening with pulmonary function tests and high-resolution CT, identification of UIP and honeycombing patterns, and treatment considerations involving immunomodulatory and antifibrotic therapies. Multidisciplinary collaboration, patient education, close monitoring, infection prevention, and timely lung transplant evaluation are also emphasized to help slow ILD progression and preserve lung function.
Recognizing and Managing RA-Associated ILD
August 2026
39:02 m
This webcast features a case-based discussion on recognizing and managing rheumatic disease-associated interstitial lung disease (ILD), including rheumatoid arthritis-associated ILD and systemic sclerosis-associated ILD. Through practical clinical scenarios, Amanda Sell, PA-C and Kelsey Cramer, MSN, AGACNP-BC, DNP review key warning signs such as progressive shortness of breath, dry cough, inspiratory crackles, exertional oxygen desaturation, reduced DLCO, and high-risk serologic findings. The session highlights early screening with pulmonary function tests and high-resolution CT, identification of UIP and honeycombing patterns, and treatment considerations involving immunomodulatory and antifibrotic therapies. Multidisciplinary collaboration, patient education, close monitoring, infection prevention, and timely lung transplant evaluation are also emphasized to help slow ILD progression and preserve lung function.
Recognizing and Managing RA-Associated ILD
August 2026
17:35 m
This webcast features a case-based discussion on recognizing and managing rheumatic disease-associated interstitial lung disease (ILD), including rheumatoid arthritis-associated ILD and systemic sclerosis-associated ILD. Through practical clinical scenarios, Kristy Delaney, APRN review key warning signs such as progressive shortness of breath, dry cough, inspiratory crackles, exertional oxygen desaturation, reduced DLCO, and high-risk serologic findings. The session highlights early screening with pulmonary function tests and high-resolution CT, identification of UIP and honeycombing patterns, and treatment considerations involving immunomodulatory and antifibrotic therapies. Multidisciplinary collaboration, patient education, close monitoring, infection prevention, and timely lung transplant evaluation are also emphasized to help slow ILD progression and preserve lung function.
Recognizing and Managing RA-Associated ILD
August 2026
18:47 m
This webcast features a case-based discussion on recognizing and managing rheumatic disease-associated interstitial lung disease (ILD), including rheumatoid arthritis-associated ILD and systemic sclerosis-associated ILD. Through practical clinical scenarios, Heather Bachert, MSN, ANP-BC and Iris Zink, NP review key warning signs such as progressive shortness of breath, dry cough, inspiratory crackles, exertional oxygen desaturation, reduced DLCO, and high-risk serologic findings. The session highlights early screening with pulmonary function tests and high-resolution CT, identification of UIP and honeycombing patterns, and treatment considerations involving immunomodulatory and antifibrotic therapies. Multidisciplinary collaboration, patient education, close monitoring, infection prevention, and timely lung transplant evaluation are also emphasized to help slow ILD progression and preserve lung function.
Recognizing and Managing RA-Associated ILD
August 2026
24:50 m
This webcast features a case-based discussion on recognizing and managing rheumatic disease-associated interstitial lung disease (ILD), including rheumatoid arthritis-associated ILD and systemic sclerosis-associated ILD. Through practical clinical scenarios, Rebekah Edwards, DNP, FNP-C and Candace Ryan, PA-C review key warning signs such as progressive shortness of breath, dry cough, inspiratory crackles, exertional oxygen desaturation, reduced DLCO, and high-risk serologic findings. The session highlights early screening with pulmonary function tests and high-resolution CT, identification of UIP and honeycombing patterns, and treatment considerations involving immunomodulatory and antifibrotic therapies. Multidisciplinary collaboration, patient education, close monitoring, infection prevention, and timely lung transplant evaluation are also emphasized to help slow ILD progression and preserve lung function.
Recognizing and Managing RA-Associated ILD
August 2026
28:38 m
This webcast features a case-based discussion on recognizing and managing rheumatic disease-associated interstitial lung disease (ILD), including rheumatoid arthritis-associated ILD and systemic sclerosis-associated ILD. Through practical clinical scenarios, Iris Zink, MSN, ANP, RN-BC and Heather Bachert, NP review key warning signs such as progressive shortness of breath, dry cough, inspiratory crackles, exertional oxygen desaturation, reduced DLCO, and high-risk serologic findings. The session highlights early screening with pulmonary function tests and high-resolution CT, identification of UIP and honeycombing patterns, and treatment considerations involving immunomodulatory and antifibrotic therapies. Multidisciplinary collaboration, patient education, close monitoring, infection prevention, and timely lung transplant evaluation are also emphasized to help slow ILD progression and preserve lung function.
Recognizing and Managing RA-Associated ILD
August 2026
18:19 m
This webcast features a case-based discussion on recognizing and managing rheumatic disease-associated interstitial lung disease (ILD), including rheumatoid arthritis-associated ILD and systemic sclerosis-associated ILD. Through practical clinical scenarios, Christine Susanne Anderson, NP-C and Wendy Simmons, PA-C, DFAAPA review key warning signs such as progressive shortness of breath, dry cough, inspiratory crackles, exertional oxygen desaturation, reduced DLCO, and high-risk serologic findings. The session highlights early screening with pulmonary function tests and high-resolution CT, identification of UIP and honeycombing patterns, and treatment considerations involving immunomodulatory and antifibrotic therapies. Multidisciplinary collaboration, patient education, close monitoring, infection prevention, and timely lung transplant evaluation are also emphasized to help slow ILD progression and preserve lung function.
Recognizing and Managing RA-Associated ILD
August 2026
28:14 m
This webcast features a case-based discussion on recognizing and managing rheumatic disease-associated interstitial lung disease (ILD), including rheumatoid arthritis-associated ILD and systemic sclerosis-associated ILD. Through practical clinical scenarios, Shannon Benesh, DNP, NP-C and Monica Richey, MSN, ANP-BC review key warning signs such as progressive shortness of breath, dry cough, inspiratory crackles, exertional oxygen desaturation, reduced DLCO, and high-risk serologic findings. The session highlights early screening with pulmonary function tests and high-resolution CT, identification of UIP and honeycombing patterns, and treatment considerations involving immunomodulatory and antifibrotic therapies. Multidisciplinary collaboration, patient education, close monitoring, infection prevention, and timely lung transplant evaluation are also emphasized to help slow ILD progression and preserve lung function.
Recognizing and Managing RA-Associated ILD
August 2026
27:10 m
This webcast features a case-based discussion on recognizing and managing rheumatic disease-associated interstitial lung disease (ILD), including rheumatoid arthritis-associated ILD and systemic sclerosis-associated ILD. Through practical clinical scenarios, Courtney Gibbons, NP and Heather Mambretti, PA-C, MPAS review key warning signs such as progressive shortness of breath, dry cough, inspiratory crackles, exertional oxygen desaturation, reduced DLCO, and high-risk serologic findings. The session highlights early screening with pulmonary function tests and high-resolution CT, identification of UIP and honeycombing patterns, and treatment considerations involving immunomodulatory and antifibrotic therapies. Multidisciplinary collaboration, patient education, close monitoring, infection prevention, and timely lung transplant evaluation are also emphasized to help slow ILD progression and preserve lung function.
Uncovering the Clues: A Case-Based Journey Through ILD in Rheumatic Disease
April 2026
41:28 m
This webcast brings together rheumatology and pulmonology experts to explore the recognition and management of interstitial lung disease (ILD) in patients with autoimmune conditions, using real-world case discussions to guide clinical decision-making. Through cases of rheumatoid arthritis–associated ILD and systemic sclerosis with progressive pulmonary fibrosis, Mary Elliott, PA-C, PhD and Alanna Kavanaugh, EdD(c), FNP-BC, MSN, BSN, CCRN highlight key risk factors, early clinical signs such as dyspnea and inspiratory crackles, and the importance of diagnostic tools including pulmonary function tests and high-resolution CT imaging. The discussion emphasizes identifying high-risk patients, understanding imaging patterns like usual interstitial pneumonia (UIP), and initiating timely, evidence-based treatment strategies. The session also examines evolving treatment approaches, including immunosuppressive therapies, antifibrotic agents, and biologics, while addressing common clinical dilemmas such as methotrexate use and therapy selection. A strong focus is placed on multidisciplinary collaboration, ongoing monitoring, and individualized patient care, including considerations for transplant referral and supportive interventions. Overall, this webcast provides a practical, case-based overview to help clinicians improve early detection, optimize management, and better coordinate care for patients with autoimmune-related ILD.
Uncovering the Clues: A Case-Based Journey Through ILD in Rheumatic Disease
April 2026
20:51 m
This webcast presents a case-based discussion on recognizing and managing interstitial lung disease (ILD) in patients with rheumatic conditions, including rheumatoid arthritis and systemic sclerosis. Through real-world patient scenarios, Wendy Simmons, PA-C, DFAAPA and Christine Anderson, NP-C highlight key risk factors such as seropositivity, age, and progressive respiratory symptoms, along with important findings like inspiratory crackles and exertional desaturation. The session emphasizes early detection using pulmonary function tests and high-resolution CT imaging, identification of fibrotic patterns like UIP, and timely initiation of immunomodulatory and antifibrotic therapies. The importance of multidisciplinary collaboration, proactive monitoring, and early referral for transplant evaluation and supportive care is reinforced to help preserve lung function and improve patient outcomes.
Uncovering the Clues: A Case-Based Journey Through ILD in Rheumatic Disease
April 2026
23:32 m
This webcast provides a case-based discussion on recognizing and managing interstitial lung disease (ILD) in patients with rheumatic diseases, including rheumatoid arthritis and systemic sclerosis. Through real-world patient scenarios, Robert Laugherty, PA-C and Erica Ludtke, NP highlight key risk factors such as high serologic titers, age, and progressive respiratory symptoms, along with important findings like inspiratory crackles and exertional desaturation. The session emphasizes early screening with pulmonary function tests and high-resolution CT imaging, identification of fibrotic patterns like UIP, and timely initiation of immunomodulatory and antifibrotic therapies. The importance of close collaboration between rheumatology and pulmonology, early intervention, and proactive monitoring is reinforced to help slow disease progression and improve patient outcomes.
Uncovering the Clues: A Case-Based Journey Through ILD in Rheumatic Disease
April 2026
19:51 m
This webcast features a case-based discussion on recognizing and managing interstitial lung disease (ILD) in patients with rheumatic conditions, including rheumatoid arthritis and systemic sclerosis. Through practical clinical scenarios, Iris Zink, MSN, ANP-BC, APRN and Heather Bachert, MSN, ANP-BC highlight key risk factors such as high serologic markers, age, and progressive respiratory symptoms, along with important findings like inspiratory crackles and exertional desaturation. The session emphasizes early detection using pulmonary function tests and high-resolution CT imaging, identification of fibrotic patterns like UIP, and timely initiation of immunomodulatory and antifibrotic therapies. The importance of multidisciplinary collaboration, early referral for transplant evaluation, and supportive interventions such as pulmonary rehabilitation is reinforced to help preserve lung function and improve patient outcomes.
Uncovering the Clues: A Case-Based Journey Through ILD in Rheumatic Disease
April 2026
13:12 m
This webcast presents a case-based discussion on recognizing and managing interstitial lung disease (ILD) in patients with rheumatic conditions, including rheumatoid arthritis and systemic sclerosis. Through real-world patient cases, Janine Shinn, PA-C and Jasmine McElhany, PA highlight key risk factors such as age, seropositivity, and progressive respiratory symptoms, along with important findings like inspiratory crackles and exertional desaturation. The session emphasizes early screening with pulmonary function tests and high-resolution CT imaging, identification of high-risk patterns like UIP, and timely initiation of immunomodulatory and antifibrotic therapies. The importance of multidisciplinary collaboration, proactive monitoring, and early referral for advanced care is reinforced to help improve patient outcomes.
Uncovering the Clues: A Case-Based Journey Through ILD in Rheumatic Disease
April 2026
33:58 m
This webcast presents a case-based discussion on identifying and managing interstitial lung disease (ILD) in patients with rheumatic conditions, including rheumatoid arthritis and systemic sclerosis. Through real-world patient scenarios, Amanda Sell, PA-C and Kelsey Cramer, AGACNP-BC, DNP highlight key risk factors such as high serologic titers, age, and progressive respiratory symptoms, along with important clinical findings like inspiratory crackles and exertional desaturation. The session emphasizes early screening with pulmonary function tests and high-resolution CT imaging, recognition of fibrotic patterns like UIP, and timely initiation of immunomodulatory and antifibrotic therapies. The discussion also underscores the importance of multidisciplinary collaboration, proactive monitoring, and early referral for advanced care, including transplant evaluation, to improve patient outcomes.
Uncovering the Clues: A Case-Based Journey Through ILD in Rheumatic Disease
April 2026
29:09 m
This webcast offers a case-based exploration of identifying and managing interstitial lung disease (ILD) in patients with rheumatic diseases, including rheumatoid arthritis and systemic sclerosis. Through real-world patient scenarios, clinicians Lori Reed, NP and Audrey Gibson, PA-C highlight key risk factors such as high serologic titers, age, and progressive respiratory symptoms, along with important clinical findings like inspiratory crackles and exertional desaturation. The discussion emphasizes early detection using pulmonary function tests and high-resolution CT imaging, recognition of fibrotic patterns like UIP, and timely initiation of immunomodulatory and antifibrotic therapies. The session also underscores the importance of multidisciplinary collaboration, proactive monitoring, and comprehensive patient care to help slow disease progression and improve outcomes.
Uncovering the Clues: A Case-Based Journey Through ILD in Rheumatic Disease
April 2026
21:10 m
This webcast provides a case-based overview of identifying and managing interstitial lung disease (ILD) in patients with rheumatic diseases, including rheumatoid arthritis and systemic sclerosis. Through practical clinical scenarios, experts Michele Cerra, MSN, FNP-BC and Christine Anderson, NP-C highlight key warning signs such as progressive shortness of breath, fatigue, and exertional desaturation, along with high-risk features like seropositivity and diffuse disease. The discussion emphasizes early diagnosis using pulmonary function tests and high-resolution CT imaging, recognition of fibrotic patterns like UIP, and timely initiation of immunomodulatory and antifibrotic therapies. The session also underscores the importance of multidisciplinary collaboration, proactive monitoring, and comprehensive supportive care to improve patient outcomes.
Uncovering the Clues: A Case-Based Journey Through ILD in Rheumatic Disease
April 2026
37:44 m
This webcast provides a practical, case-based look at identifying and managing interstitial lung disease (ILD) in patients with autoimmune conditions, with a focus on rheumatoid arthritis and systemic sclerosis. Through real-world scenarios, expert clinicians, Betsy Kirchner, DNP and Jessica Glennie, MSN, APRN highlight key risk factors, early warning signs like exertional dyspnea and inspiratory crackles, and the importance of timely screening with pulmonary function tests and high-resolution CT imaging. The discussion emphasizes collaborative care between rheumatology and pulmonology, outlining treatment strategies that balance immunosuppression and antifibrotic therapy to slow disease progression. Attendees will gain actionable insights on early detection, multidisciplinary management, and optimizing patient outcomes in ILD.
Uncovering the Clues: A Case-Based Journey Through ILD in Rheumatic Diseas
April 2026
30:14 m
This webcast features a case-based discussion exploring the critical connection between rheumatologic diseases and interstitial lung disease (ILD), emphasizing early recognition, risk stratification, and collaborative care. Through real-world patient cases—including rheumatoid arthritis–associated ILD and systemic sclerosis–related lung involvement—experts, Iris Zink, MSN, ANP-BC, APRN and Heather Bachert, MSN, ANP-BC, highlight key clinical warning signs such as progressive dyspnea, fatigue, and high-risk serologic markers. The session underscores the importance of timely screening with pulmonary function tests and high-resolution CT imaging, as well as early referral to pulmonology. Treatment strategies are reviewed, including the role of immunomodulators and antifibrotic therapies in slowing disease progression. Ultimately, this discussion reinforces the need for multidisciplinary management and proactive monitoring to improve outcomes and quality of life for patients with autoimmune-related lung disease.
Emerging Therapies in ILD
October 2025
07:37 m
In this presentation, Corinne Young reviews the latest advances in therapies for interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF), highlighting the promising results of nerandomilast, a phosphodiesterase-4B inhibitor with both antifibrotic and immunomodulatory effects. Phase 3 trials (FIBRONEER-IPF and FIBRONEER-ILD) demonstrated that twice-daily nerandomilast slowed lung function decline and improved outcomes across patient populations, including those with autoimmune-related disease. The discussion also covers the drug’s safety profile—showing fewer gastrointestinal side effects compared to existing antifibrotic agents—and emerging treatments such as inhaled treprostinil, which is being studied for pulmonary fibrosis beyond pulmonary hypertension. With multiple new agents and combination therapies on the horizon, these developments represent meaningful progress in the treatment and management of fibrotic lung disease.
Antifibrotic Therapy
October 2025
06:40 m
In this session, Corinne Young reviews the evolution of antifibrotic therapies for interstitial lung disease, beginning with the 2015 U.S. approval of pirfenidone (Esbriet) for idiopathic pulmonary fibrosis (IPF). Pirfenidone works by targeting TGF-β and TNF-α to slow fibroblast proliferation and collagen synthesis, though patients often experience gastrointestinal side effects and fatigue. The discussion also covers nintedanib (Ofev), a tyrosine kinase inhibitor that blocks multiple growth factor pathways (VEGF, FGF, PDGF) and is now approved for both IPF and other progressive fibrotic lung diseases. Clinical trials such as CAPACITY, ASCEND, INPULSIS, and INBUILD demonstrated that these antifibrotics significantly slow the rate of lung function decline and disease progression. The talk concludes by emphasizing careful side-effect management, liver monitoring, and appropriate patient selection to optimize outcomes with these cornerstone antifibrotic therapies.
The Rheum-Pulm Interface: Bridging Specialties in SARD-ILD
October 2025
11:21 m
In this session, Corinne Young and Wendy Simmons highlight the importance of a multidisciplinary approach to managing interstitial lung disease (ILD) in patients with systemic autoimmune and rheumatologic disorders. Collaboration between rheumatology, pulmonology, and radiology teams is key to early recognition, diagnosis, and treatment planning—especially given the high risk of ILD-related morbidity and mortality in conditions like systemic sclerosis, rheumatoid arthritis, lupus, and Sjögren’s syndrome. The discussion reviews ACR screening guidelines, emphasizing the role of high-resolution CT imaging, pulmonary function testing, and oxygen desaturation monitoring. It also covers evidence-based first-line and escalation therapies, including mycophenolate, cyclophosphamide, and rituximab, while underscoring the need for frequent assessment, early intervention, and coordinated care to improve patient outcomes.
Understanding the Landscape of ILD: Burden, Pathophysiology, and Classification
October 2025
20:49 m
In this presentation, pulmonary nurse practitioner Corinne Young and rheumatology physician assistant Wendy Simmons explore the complex relationship between interstitial lung disease (ILD) and connective tissue diseases (CTDs). Together, they provide a multidisciplinary perspective—highlighting how collaboration between pulmonology, rheumatology, and radiology leads to earlier diagnosis, better management, and improved outcomes. The session covers ILD classifications, common causes such as autoimmune disorders, environmental exposures, and drug toxicities, as well as diagnostic tools including high-resolution CT imaging, pulmonary function testing, and serologic assays. The speakers also discuss the importance of recognizing progressive phenotypes, understanding imaging patterns like UIP and NSIP, and tailoring therapy based on disease behavior. This session emphasizes that in ILD, time is lung—early recognition and coordinated care are essential to preserving function and extending quality of life.
IPF & PPF: Natural History, Diagnosis, and Management
October 2025
07:52 m
In this educational session, Corinne Young breaks down the underlying mechanisms, progression, and management of idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILDs). The discussion covers common genetic and environmental risk factors—including family history, smoking, and occupational exposures—and explains how chronic inflammation leads to fibrosis and loss of lung elasticity. Listeners gain a clear understanding of how progressive pulmonary fibrosis is identified through lung function tests (FVC, DLCO) and imaging changes over time. The presentation also addresses treatment strategies, highlighting when corticosteroids may be appropriate, why long-term steroid use is limited, and how newer antifibrotic and immunomodulatory therapies are improving outcomes for patients with fibrotic lung disease.
Rheumatoid Arthritis Associated ILD, End Stage Therapy, and Multidisciplinary Care
October 2025
02:31 m
In this discussion, Corinne Young explores the complexities of managing patients with advanced interstitial lung disease, emphasizing the importance of early referral for lung transplant and cautious evaluation of unproven stem cell therapies. The conversation highlights how patients are sometimes misled into costly, non-evidence-based treatments abroad and underscores that only limited data exist for hematopoietic stem cell use in this setting. The speakers stress the critical role of multidisciplinary collaboration among pulmonology, rheumatology, gastroenterology, and cardiology teams, along with early conversations about palliative care and quality-of-life goals. With new therapies emerging, the focus remains on preserving lung function, aligning treatment with patient priorities, and ensuring compassionate, coordinated care for those facing progressive disease.
What Can Pulmonology APPs Do Once They've Established an ILD Diagnosis to Aid in Potential Rheumatology Workups?
July 2025
01:42 m
Once you've confirmed a diagnosis of interstitial lung disease (ILD), what’s next? In this practical and fast-paced discussion, Amanda Mixon, PA-C, shares actionable steps for evaluating patients for underlying autoimmune or connective tissue diseases. Learn what symptoms to ask about—joint pain, morning stiffness, skin lesions, Raynaud’s, dry eyes or mouth—and how labs and rheumatology collaboration can support early detection and accurate diagnosis. This video offers clinical pearls for APPs working in pulmonology who want to strengthen their diagnostic acumen and build better cross-specialty communication with rheumatology colleagues. Topics covered: – What symptoms may signal underlying rheumatic disease in ILD patients – Key lab tests to guide your differential – When to refer to rheumatology – The value of real-time collaboration across specialties ILD care is better together. Watch now to improve your approach to autoimmune workups in pulmonary patients.
Scleroderma Treatment
July 2025
01:52 m
In this focused discussion, Amanda Mixon, PA-C shares a practical approach to managing patients with systemic sclerosis (Scleroderma), with an emphasis on individualized care based on disease manifestation. From echocardiograms to pulmonary imaging, medication choices to vascular complications, this talk provides key insights into how APPs can tailor care to improve outcomes. Learn how to approach limited vs. diffuse Scleroderma, when to avoid glucocorticoids, and how to manage complications like digital ulcers and pulmonary involvement. Key takeaways include: – When to use echocardiograms, CT scans, and other diagnostics – Medication strategies: Mycophenolate, Selenomab, CCBs, ARBs, and more – Avoiding glucocorticoids in diffuse disease and managing risk of renal crisis – Treating symptomatically: digital ulcers, skin fibrosis, and blood flow support This is a must-watch for APPs in rheumatology, pulmonology, or primary care managing patients with Scleroderma.
Systemic Sclerosis Presentation
July 2025
11:52 m
In this powerful and personal clinical reflection, Amanda Mixon, PA-C, shares her journey treating patients with diffuse systemic sclerosis (Scleroderma), including key lessons learned from working at a major Scleroderma center at Northwestern. From building trust with colleagues to managing life-threatening complications like Scleroderma Renal Crisis, this video offers invaluable insights for APPs and clinicians navigating this complex autoimmune disease. You’ll hear firsthand experiences treating patients with severe skin involvement, pulmonary fibrosis, digital ulcers, GI complications, and early vasculopathy. Learn why RNA polymerase III positivity is a red flag, how to differentiate diffuse from limited SSc, and why early diagnosis and treatment are essential. What you’ll learn: – What distinguishes diffuse Scleroderma from limited forms – Clinical signs to recognize early: Raynaud’s, skin tightening, telangiectasia – The dangers of steroid use and Scleroderma Renal Crisis – Why collaboration and early referral to SSc centers can save lives – Real stories and clinical pearls from treating high-risk patients This is a must-watch for any clinician managing autoimmune diseases—especially those treating interstitial lung disease, GI complications, or vasculitis related to Scleroderma.
Idiopathic Inflammatory Myopathies and Pulmonary Disorders Including ILD
July 2025
04:59 m
Inflammatory myopathies—like dermatomyositis, polymyositis, and inclusion body myositis—can be difficult to diagnose and manage, especially when they overlap with interstitial lung disease (ILD). In this clinical discussion, Amanda Mixon, PA-C, breaks down what to look for, from subtle signs like "mechanic's hands" to more serious red flags like MDA5-positive rapidly progressive ILD. Special attention is given to anti-synthetase syndrome, a condition often associated with ILD, arthritis, and elevated CK levels, and how antibody testing (e.g., Jo-1, SSA, MDA5) can guide diagnosis and urgency of care. You’ll also learn how to approach cancer screenings in patients with dermatomyositis and why a full malignancy workup is essential. What you'll learn: – How to identify anti-synthetase syndrome and inflammatory myopathies – Key clinical signs: weakness, mechanic’s hands, non-erosive arthritis – Understanding the myositis antibody panel and its clinical utility – The connection between dermatomyositis and malignancy risk – When and how to conduct a thorough cancer screening – Treatments including JAK inhibitors, IVIG, and rituximab Perfect for APPs, pulmonologists, and rheumatology teams, this video empowers you to catch early signs, personalize diagnostics, and take action.
Limited Cutaneous Scleroderma Presentation
July 2025
01:48 m
In this quick but focused clinical overview, Amanda Mixon, PA-C, explains how to identify and differentiate limited systemic sclerosis (also known as CREST syndrome) from diffuse scleroderma. Associated with centromere antibodies, limited scleroderma primarily affects the distal extremities and face, and while skin involvement is less severe, patients face distinct long-term risks—especially pulmonary hypertension. This video breaks down the classic CREST acronym (Calcinosis, Raynaud’s, Esophageal dysmotility, Sclerodactyly, and Telangiectasias), along with practical tips for early recognition and long-term management. What you'll learn: – How to recognize clinical features of limited scleroderma – The role of centromere antibodies vs. SCL-70 in diagnosis – Early signs like Raynaud’s and esophageal symptoms – What to monitor for in years 5–10: pulmonary hypertension, vascular disease – Differentiating CREST from diffuse disease This is an essential update for APPs and clinicians managing autoimmune connective tissue disease, especially in patients with progressive symptoms involving the skin, GI tract, and lungs.
Sjogren’s Disease and ILD
July 2025
01:43 m
In this concise and clinically insightful discussion, Amanda Mixon, PA-C, breaks down what to look for when suspecting Sjögren’s syndrome—an autoimmune condition marked by chronic dry eye and dry mouth, fatigue, and systemic manifestations. Often associated with SSA and SSB antibodies, Sjögren’s can overlap with interstitial lung disease (ILD), making it especially important for pulmonary and rheumatology providers to recognize early. Learn how to distinguish classic symptoms from environmental causes, when to consider antibody testing, and which patients may be at higher risk for more severe complications like ILD. What you’ll learn: – Clinical clues for identifying Sjögren’s in practice – Role of SSA and SSB antibodies in diagnosis – Recognizing extra-glandular manifestations: fatigue, arthritis, rashes – When to suspect ILD in Sjögren’s patients – Medication options and early steroid use considerations Whether you’re in primary care, pulmonology, or rheumatology, this video equips you to ask the right questions and understand the systemic risks behind what may appear to be “just dry mouth.”
Industry Resources
Identifying and Monitoring Autoimmune ILD | Insights in ILD
Pulmonary Function Tests (PFTs) Pocket Guide | Insights in ILD
HRCT Pocket Guide | Insights in ILD
History Taking Pocket Guide | Insights in ILD
WANT EXPERT PERSPECTIVES ON INTERSTITIAL LUNG DISEASE?
Imaging Atlas of Interstitial Lung Diseases | Insights in ILD
Rad Rounds UIP to IPF Mobile Application
Rad Rounds - UIP to IPF is an innovative, peer-reviewed resource that provides practicing and future pulmonologists and radiologists with training and references for recognizing and evaluating usual interstitial pneumonia (UIP) and interstitial lung diseases (ILDs) on high resolution computed tomography (HRCT). Through this application the user can access learning materials such as a step-by-step pattern recognition algorithm, utilizing user-provided HRCT scans, an interactive UIP/ILD glossary and image gallery to further assist in the evaluative process, several “test your knowledge” quizzes, and a series of short informational videos, covering subjects such as: Basic HRCT Technique, Imaging Positions, and Recognizing Features of ILD on HRCT. This app is ideal for: radiologists that would like to use the interactive algorithm to help assess their HRCT scans, pulmonologists that want to evaluate their own cases or learn more about HRCT in the diagnosis of ILD, and medical students and residents that want to learn about HRCT and ILD. Download now and find out: Is It UIP? Available on the App Store: https://apps.apple.com/us/app/rad-rounds-uip-to-ipf/id1327938328 Available on Google Play: https://play.google.com/store/apps/details?id=com.boehringer.radiologyrounds&hl=en_US
The Importance Of Taking A Patient's History In ILD
A Day In The Life Of A Rheumatology App: A Focus On Interstitial Lung Disease
A Day In The Life Of A Pulmonary App: A Focus On Interstitial Lung Disease
News
News
Real-world characteristics of trastuzumab deruxtecan-related interstitial lung disease in Japanese patients with breast cancer and gastric cancer
September 2026
CONCLUSIONS: Most T-DXd-related ILD cases were mild/moderate and corticosteroid-responsive; DAD pattern was associated with higher mortality. These findings underscore the importance of vigilant monitoring, early recognition, and prompt corticosteroid treatment to mitigate fatal T-DXd-related ILD.
Forced Vital Capacity and Six-Minute Walk Test as Indicators of Interstitial Lung Disease Extent on High-Resolution Computed Tomography in Systemic Sclerosis
September 2026
CONCLUSION: FVC alone may serve as a practical functional indicator of ILD extent, particularly where HRCT access is limited. Routine addition of 6MWT distance is not justified solely for estimating ILD extent, although the 6MWT remains valuable for assessing functional capacity and exertional desaturation.
Improvement of interstitial lung disease during brodalumab treatment in a patient with psoriasis and systemic immune-mediated inflammation
September 2026
No abstract
Trastuzumab Deruxtecan-Associated Pneumonitis in Non-Breast Solid Tumors: A Retrospective Cohort Study
September 2026
CONCLUSION: T-DXd-associated pneumonitis disproportionately affects patients with lung cancer and confers substantial mortality risk. A higher T-DXd dose and a short interval from prior therapy may increase pneumonitis risk but require validation in larger cohorts.
Risks of adverse respiratory outcomes in adults with cancer over the course of survivorship compared with cancer-free individuals: a matched cohort study using linked English electronic health records
September 2026
BACKGROUND: We aimed to compare the risks of developing new chronic respiratory conditions, or exacerbating existing ones in survivors of 20 common cancers vs. cancer-free individuals.
Combined Pulmonary Fibrosis and Emphysema: Clinicoradiological Parameters Associated with Fibrosis Patterns
September 2026
CONCLUSION: Although comorbidities were found to be significantly higher in the UIP pattern compared to the NSIP pattern, the CCI was similar. As more than half of patients with CPFE had elevated sPAP, pulmonary hypertension should also be considered when evaluating these patients.
The management of complex patients with inoperable stage III NSCLC: practical lessons from case-based discussion
September 2026
BACKGROUND: Standard of care for inoperable and/or unresectable stage III non-small cell lung cancer (NSCLC) is concurrent chemoradiotherapy followed by 12 months of adjuvant durvalumab. Many patients are ineligible due to poor fitness, comorbidity or concerns around their ability to tolerate concurrent therapy or immunotherapy. As a result, these patients experience inferior outcomes.
Antibody-Drug Conjugates in the Treatment of Esophageal Cancer
September 2026
Esophageal cancer remains one of the most lethal malignancies worldwide, with particularly poor outcomes following disease progression after first-line chemoimmunotherapy. Antibody-drug conjugates (ADCs) have emerged as a transformative therapeutic class that combines the targeting precision of monoclonal antibodies with potent cytotoxic payloads, enabling selective tumor cell killing while minimizing off-target toxicity. In the management of advanced esophageal cancer, I advocate for the...
Autoantibody Profiles and Clinical Correlations in Systemic Sclerosis: A Cross-Sectional Study
September 2026
CONCLUSION: SSc in this cohort showed female predominance with frequent arthralgia and respiratory symptoms. Anti-Scl-70 antibodies were most common, strongly linked to diffuse disease and ILD. ANA profiling provides disease characterization in Indian SSc.
Effects of dust exposure on IGF1 and autophagy related to coal workers' pneumoconiosis
September 2026
CONCLUSION: Age, early initial working age, prolonged dust exposure, smoking, elevated white blood cell count and increased AST/ALT ratio are correlated factors for coal workers' pneumoconiosis. Synchronous alterations in IGF1 upregulation, elevated phosphorylation levels of PI3K and AKT, and abnormal expression of autophagy-related markers were observed in pneumoconiosis patients and silica-stimulated macrophages, revealing correlative molecular links among these molecules in pneumoconiosis...
A Rare Case of COPA Syndrome: Multisystem Relapse and Fatal Septic Complication
September 2026
COPA syndrome is a rare autosomal dominant autoimmune disorder caused by COPA gene mutations, leading to immune dysregulation and multisystem involvement. We report a 45-year-old man with recurrent respiratory failure, haemoptysis, renal dysfunction and arthritis. Symptoms began at Age 27 with diffuse alveolar damage requiring mechanical ventilation. Imaging showed progressive interstitial lung disease and biopsy revealed follicular bronchiolitis. Immunosuppression provided temporary...
Juvenile dermatomyositis in Latvia: clinical, radiologic, laboratory, and therapeutic findings from 2010 to 2025
September 2026
CONCLUSIONS: This retrospective study covering 2010-2025 shows that JDM in Latvia generally presents similarly to that described in other cohorts of children. Proximal muscle weakness and characteristic skin findings were common, while CPK elevation was observed in only a subset of children. Most children responded well to treatment with glucocorticosteroids and methotrexate, with remission achieved in the majority within the first year and only rare need for biologic therapy. Muscle MRI was...
Interstitial pneumonia signals of apalutamide, darolutamide, and enzalutamide in FAERS and JADER
September 2026
CONCLUSION: The three ARSIs showed heterogeneous interstitial pneumonia reporting patterns in FAERS and JADER. Apalutamide and darolutamide demonstrated more consistent disproportionality signals, whereas enzalutamide showed weaker signal strength but a reproducible early-onset pattern among reports with valid time-to-onset information. These findings support continued pharmacovigilance and early clinical monitoring, while recognizing that spontaneous reporting signals cannot establish causality...
Novel Dosing, Monitoring, and Safety Assessment for Cyclosporine in the Management of ABCA3 Surfactant Dysfunction in an Infant
September 2026
No abstract
Organelle Crosstalk and Metabolic Reprogramming in Idiopathic Pulmonary Fibrosis: Mechanisms and Therapeutic Implications
September 2026
Idiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease of unknown cause, marked by excessive deposition of extracellular matrix (ECM) components such as collagen. This pathological accumulation results in progressive destruction of the lung architecture and ultimately leads to respiratory failure. Growing evidence indicates that dysfunction across multiple cell types is an important driver of IPF. Nevertheless, its underlying pathobiology remains incompletely understood. The...
Top Ten Tips Palliative Care Clinicians Should Know About Caring for People with Interstitial Lung Diseases
September 2026
Interstitial lung diseases (ILD) represent a heterogenous group of illnesses with significant multidimensional suffering and varied prognoses. Integration of palliative care (PC), though beneficial, is limited for this group of individuals. The complex care needs of people with ILD and their caregivers are underrecognized and incompletely addressed. This gap necessitates shared care by a multidisciplinary team along the illness trajectory. PC clinicians need to understand the illness patterns,...
Effect of an acute exercise bout on alveolar-capillary membrane permeability and interstitial fluid accumulation in COPD
September 2026
Exertional dyspnoea is a debilitating symptom in chronic obstructive pulmonary disease (COPD) and often persists after the cessation of exercise. The underlying mechanisms are not fully understood, and a potential contributing factor that has not previously been investigated is alveolar-capillary membrane breaching with extravasation of fluid into the lungs. Sixteen individuals with COPD and 16 age- and sex-matched healthy controls were included. Alveolar-capillary membrane permeability was...
A regulatory network underlying idiopathic pulmonary fibrosis
September 2026
CONCLUSIONS: These findings refine the molecular landscape of the chromosome 11p15.5 IPF susceptibility locus and prioritize BRSK2 as a candidate component of an IPF-associated profibrotic fibroblast state. Its causal contribution, direct regulatory relationships, and therapeutic tractability require targeted mechanistic validation.
VV-ECMO therapy and diagnostic analysis of a patient with anti-synthetase syndrome complicated by severe acute respiratory distress syndrome
September 2026
Anti-synthetase syndrome (ASS) is a rare autoimmune disorder, and cases complicated by severe acute respiratory distress syndrome (ARDS) requiring veno-venous extracorporeal membrane oxygenation (VV-ECMO) are exceedingly uncommon and clinically challenging. On July 6, 2025, a 71-year-old woman with ASS complicated by severe ARDS was admitted to the department of intensive care unit of Huanggang Central Hospital Affiliated to Yangtze University. She presented with a 25-day history of anorexia and...
Baseline disease activity index and forced vital capacity predict clinically meaningful complications and mortality in systemic sclerosis
September 2026
CONCLUSION: Baseline mDAI and forced vital capacity independently predict disease-related clinically meaningful complications and mortality in SSc. The mDAI provides a simple, feasible tool for risk stratification beyond progression of interstitial lung disease.
